{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:16:00Z","timestamp":1785816960856,"version":"3.56.0"},"reference-count":101,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Globally, there are two major poxvirus outbreaks: mpox, caused by the monkeypox virus, and lumpy skin disease, caused by the lumpy skin disease virus. While vaccines for both diseases exist, there is a need for improved vaccines. The original vaccines used to eradicate smallpox, which also protect from the disease now known as mpox, are no longer acceptable. This is mainly due to the risk of serious adverse events, particularly in HIV-positive people. The next-generation vaccine for mpox prevention is modified vaccinia Ankara, which does not complete the viral replication cycle in humans and, therefore, has a better safety profile. However, two modified vaccinia Ankara immunizations are needed to give good but often incomplete protection, and there are indications that the immune response will wane over time. A better vaccine that induces a long-lived response with only one immunization is desirable. Another recently available smallpox vaccine is LC16m8. While LC16m8 contains replicating vaccinia virus, it is a more attenuated vaccine than the original vaccines and has limited side effects. The commonly used lumpy skin disease vaccines are based on attenuated lumpy skin disease virus. However, an inactivated or non-infectious vaccine is desirable as the disease spreads into new territories. This article reviews novel vaccine approaches, including mRNA and subunit vaccines, to protect from poxvirus infection.<\/jats:p>","DOI":"10.3390\/v17020186","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:42:23Z","timestamp":1737970943000},"page":"186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Approaches to Next-Generation Capripoxvirus and Monkeypox Virus Vaccines"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-1200","authenticated-orcid":false,"given":"Anna-Lise","family":"Williamson","sequence":"first","affiliation":[{"name":"Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa"},{"name":"Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dhoundiyal, S., Alam, M.A., Kaur, A., and Varshney, S. (2024). Burdening Perspectives and Treatment Modalities of Monkeypox: A Central Dogma. Infect. Disord. Drug Targets, 24.","DOI":"10.2174\/1871526523666230825164222"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32607\/20758251-2017-9-4-4-12","article-title":"40 Years without Smallpox","volume":"9","author":"Shchelkunova","year":"2017","journal-title":"Acta Naturae"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shchelkunova, G.A., and Shchelkunov, S.N. (2022). Smallpox, Monkeypox and Other Human Orthopoxvirus Infections. Viruses, 15.","DOI":"10.3390\/v15010103"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.adt4793","article-title":"Africa aims to avert an mpox pandemic","volume":"386","author":"Ndembi","year":"2024","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/23744235.2024.2399776","article-title":"First cases of mpox Clade I outside of Africa: Genetic insights on its evolution","volume":"56","author":"Branda","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S1473-3099(24)00530-9","article-title":"The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus","volume":"24","author":"Du","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102781","DOI":"10.1016\/j.tmaid.2024.102781","article-title":"Global spread of mpox Clade I: Implications for travel and public health","volume":"62","author":"Branda","year":"2024","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41564-024-01690-1","article-title":"Understanding the biology of monkeypox virus to prevent future outbreaks","volume":"9","author":"Moss","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.cmi.2023.07.011","article-title":"A contemporary review of clade-specific virological differences in monkeypox viruses","volume":"29","author":"Okwor","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.10.002","article-title":"The evolving epidemiology of monkeypox virus","volume":"68","author":"Li","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/viro.2002.1446","article-title":"Analysis of the monkeypox virus genome","volume":"297","author":"Shchelkunov","year":"2002","journal-title":"Virology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/tbed.12177","article-title":"Lumpy Skin Disease in Jordan: Disease Emergence, Clinical Signs, Complications and Preliminary-associated Economic Losses","volume":"62","author":"Abutarbush","year":"2015","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tuppurainen, E., Dietze, K., Wolff, J., Bergmann, H., Beltran-Alcrudo, D., Fahrion, A., Lamien, C.E., Busch, F., Sauter-Louis, C., and Conraths, F.J. (2021). Review: Vaccines and Vaccination against Lumpy Skin Disease. Vaccines, 9.","DOI":"10.3390\/vaccines9101136"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vandenbussche, F., Mathijs, E., Philips, W., Saduakassova, M., De Leeuw, I., Sultanov, A., Haegeman, A., and De Clercq, K. (2022). Recombinant LSDV Strains in Asia: Vaccine Spillover or Natural Emergence?. Viruses, 14.","DOI":"10.3390\/v14071429"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/tbed.13261","article-title":"Epizootic features and control measures for lumpy skin disease in south-east Serbia in 2016","volume":"66","author":"Manic","year":"2019","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tbed.13898","article-title":"Lumpy skin disease outbreaks in China, since 3 August 2019","volume":"68","author":"Lu","year":"2020","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11259-020-09780-1","article-title":"A review: Lumpy skin disease and its emergence in India","volume":"44","author":"Gupta","year":"2020","journal-title":"Vet. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.17582\/journal.hv\/2020\/7.4.97.108","article-title":"Lumpy Skin Disease Virus Infection: An Emerging Threat to Cattle Health in Bangladesh","volume":"7","author":"Kayesh","year":"2020","journal-title":"Hosts Viruses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/tbed.12889","article-title":"Epidemiological characterization of lumpy skin disease outbreaks in Russia in 2016","volume":"65","author":"Sprygin","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00550-17","DOI":"10.1128\/genomeA.00550-17","article-title":"Complete Genome Sequence of the Lumpy Skin Disease Virus Isolated from the First Reported Case in Greece in 2015","volume":"5","author":"Agianniotaki","year":"2016","journal-title":"Genome Announc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Haga, I.R., Shih, B.B., Tore, G., Polo, N., Ribeca, P., Gombo-Ochir, D., Shura, G., Tserenchimed, T., Enkhbold, B., and Purevtseren, D. (2024). Sequencing and Analysis of Lumpy Skin Disease Virus Whole Genomes Reveals a New Viral Subgroup in West and Central Africa. Viruses, 16.","DOI":"10.3390\/v16040557"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.5455\/OVJ.2024.v14.i7.19","article-title":"A new variant of lumpy skin disease virus circulating in Vietnam based on sequencing analysis of GPCR gene","volume":"14","author":"Tran","year":"2024","journal-title":"Open Vet. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Samad, M.A., Hossen, A., Karim, M.R., Uddin, A., Roy, D., Shithi, K.N., Akter, M.N., Das, T.K., Selleck, P.W., and Bulach, D.M. (2024). Complete genome sequence of a lumpy skin disease virus isolate from a 2021 outbreak of disease in Bangladesh. Microbiol. Resour. Announc., 13.","DOI":"10.1128\/mra.00667-24"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1292\/jvms.22-0250","article-title":"Molecular identification and risk factor analysis of the first Lumpy skin disease outbreak in cattle in Mongolia","volume":"84","author":"Odonchimeg","year":"2022","journal-title":"J. Vet. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.prevetmed.2018.12.001","article-title":"Neethling vaccine proved highly effective in controlling lumpy skin disease epidemics in the Balkans","volume":"181","author":"Klement","year":"2020","journal-title":"Prev. Vet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/tbed.13158","article-title":"Determination of lumpy skin disease virus in bovine meat and offal products following experimental infection","volume":"66","author":"Kononov","year":"2019","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"001849","DOI":"10.1099\/jgv.0.001849","article-title":"ICTV Virus Taxonomy Profile: Poxviridae 2023","volume":"104","author":"McInnes","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-5793(01)03144-1","article-title":"Human monkeypox and smallpox viruses: Genomic comparison","volume":"509","author":"Shchelkunov","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00705-003-0102-0","article-title":"Comparative sequence analysis of the South African vaccine strain and two virulent field isolates of Lumpy skin disease virus","volume":"148","author":"Kara","year":"2003","journal-title":"Arch. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1008140615106","article-title":"Poxvirus homologues of cellular genes","volume":"21","author":"Bugert","year":"2000","journal-title":"Virus Genes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00705-023-05938-9","article-title":"Genome sequence characterization of the unique recombinant vaccine-like lumpy skin disease virus strain Kurgan\/2018","volume":"169","author":"Sprygin","year":"2024","journal-title":"Arch. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ympev.2004.12.008","article-title":"Poxvirus genome evolution by gene gain and loss","volume":"35","author":"Hughes","year":"2005","journal-title":"Mol. Phylogenetics Evol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Senkevich, T.G., Yutin, N., Wolf, Y.I., Koonin, E.V., and Moss, B. (2021). Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes. mBio, 12.","DOI":"10.1128\/mbio.01495-21"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcdb.2016.07.015","article-title":"Membrane fusion during poxvirus entry","volume":"60","author":"Moss","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0085221","DOI":"10.1128\/JVI.00852-21","article-title":"Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells","volume":"95","author":"Schin","year":"2021","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Riccardo, V., and Pablo, G.C. (2023). Neutralization Determinants on Poxviruses. Viruses, 15.","DOI":"10.3390\/v15122396"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1016\/j.vaccine.2020.07.018","article-title":"Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus","volume":"38","author":"Xiao","year":"2020","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.virusres.2004.08.015","article-title":"The exit of vaccinia virus from infected cells","volume":"106","author":"Smith","year":"2004","journal-title":"Virus Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1016\/j.vaccine.2020.05.037","article-title":"Early smallpox vaccine manufacturing in the United States: Introduction of the \u201canimal vaccine\u201d in 1870, establishment of \u201cvaccine farms\u201d, and the beginnings of the vaccine industry","volume":"38","author":"Esparza","year":"2020","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1016\/j.vaccine.2007.10.040","article-title":"Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: The Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3","volume":"25","author":"Osborne","year":"2007","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.09.55","article-title":"The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks","volume":"8","author":"Handley","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1016\/j.vaccine.2021.08.041","article-title":"Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members","volume":"39","author":"Decker","year":"2021","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/aid.2006.0226","article-title":"Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART","volume":"23","author":"Cosma","year":"2007","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nave, L., Margalit, I., Tau, N., Cohen, I., Yelin, D., Lienert, F., and Yahav, D. (2023). Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vaccines, 11.","DOI":"10.3390\/vaccines11091410"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jiph.2024.02.015","article-title":"Breakthrough cases of mpox: One-dose vaccination is associated with milder clinical manifestations","volume":"17","author":"Allard","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3201\/eid3010.240292","article-title":"Mpox Epidemiology and Vaccine Effectiveness, England, 2023","volume":"30","author":"Charles","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"ref_50","first-page":"2400575","article-title":"Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023","volume":"29","author":"Shamier","year":"2024","journal-title":"Eurosurveillance"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.2024.20951","article-title":"Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination","volume":"332","author":"Collier","year":"2024","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: Analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00040-09","article-title":"Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model","volume":"16","author":"Meseda","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Golding","year":"2005","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-031-57165-7_19","article-title":"Treatment and Vaccination for Smallpox and Monkeypox","volume":"1451","author":"Saalbach","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Palma, J.A., Bunyatov, M.I., Hulbert, S.W., Jewett, M.C., and DeLisa, M.P. (2024). Bacterial glycoengineering: Cell-based and cell-free routes for producing biopharmaceuticals with customized glycosylation. Curr. Opin. Chem. Biol., 81.","DOI":"10.1016\/j.cbpa.2024.102500"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/bit.28169","article-title":"Augmenting glycosylation-directed folding pathways enhances the fidelity of HIV Env immunogen production in plants","volume":"119","author":"Margolin","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.vaccine.2020.08.050","article-title":"The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform","volume":"39","author":"Volkmann","year":"2021","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/CVI.00717-15","article-title":"Subtype C gp140 vaccine boosts immune responses primed by the South African AIDS vaccine initiative DNA-C2 and MVA-C HIV vaccines after more than a 2-year gap","volume":"23","author":"Gray","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Churchyard, G., Mlisana, K., Karuna, S., Williamson, A.-L., Williamson, C., Morris, L., Tomaras, G.D., De Rosa, S.C., Gilbert, P.B., and Gu, N. (2016). Sequential immunization with gp140 boosts immune responses primed by modified vaccinia Ankara or DNA in HIV-uninfected South African participants. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161753"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Borthwick, N., Fernandez, N., Hayes, P.J., Wee, E.G., Akis Yildirim, B.M., Baines, A., Baker, M., Byard, N., Conway, O., and Glaze, M. (2024). Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK. Lancet Microbe.","DOI":"10.1016\/j.lanmic.2024.100956"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mothe, B., Rosas-Umbert, M., Coll, P., Manzardo, C., Puertas, M.C., Moron-Lopez, S., Llano, A., Miranda, C., Cedeno, S., and Lopez, M. (2020). HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00823"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Xiong, Z., Xue, L., Li, X., and Zhang, Y. (2024). Assessing vaccine strategies for mpox outbreak in New York City using an age-structure model. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09551-2"},{"key":"ref_65","first-page":"e33434","article-title":"Monkeypox: Treatment, Vaccination, and Prevention","volume":"15","author":"Shah","year":"2023","journal-title":"Cureus"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"126427","DOI":"10.1016\/j.vaccine.2024.126427","article-title":"A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study","volume":"42","author":"Jordan","year":"2024","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Yasui, F., Munekata, K., Fujiyuki, T., Kuraishi, T., Yamaji, K., Honda, T., Gomi, S., Yoneda, M., Sanada, T., and Ishii, K. (2025). Single Dose of Attenuated Vaccinia Viruses Expressing H5 Hemagglutinin Affords Rapid and Long-Term Protection Against Lethal Infection with Highly Pathogenic Avian Influenza A H5N1 Virus in Mice and Monkeys. Vaccines, 13.","DOI":"10.3390\/vaccines13010074"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/S0264-410X(02)00203-7","article-title":"Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle","volume":"20","author":"Aspden","year":"2002","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Douglass, N., Omar, R., Munyanduki, H., Suzuki, A., de Moor, W., Mutowembwa, P., Pretorius, A., Nefefe, T., Schalkwyk, A.V., and Kara, P. (2021). The Development of Dual Vaccines against Lumpy Skin Disease (LSD) and Bovine Ephemeral Fever (BEF). Vaccines, 9.","DOI":"10.3390\/vaccines9111215"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Whittle, L., Chapman, R., Douglass, N., Jaffer, M., Margolin, E., Rybicki, E., and Williamson, A.L. (2023). Development of a dual vaccine against East Coast fever and lumpy skin disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1143034"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Whittle, L., Chapman, R., and Williamson, A.L. (2023). Lumpy Skin Disease-An Emerging Cattle Disease in Europe and Asia. Vaccines, 11.","DOI":"10.3390\/vaccines11030578"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","article-title":"Mpox vaccine and infection-driven human immune signatures","volume":"23","author":"Cohn","year":"2023","journal-title":"Lancet Inf. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1473-3099(23)00492-9","article-title":"Mpox in people with past infection or a complete vaccination course: A global case series","volume":"24","author":"Hazra","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1038\/s41467-024-48180-w","article-title":"Predicting vaccine effectiveness for mpox","volume":"15","author":"Berry","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1016\/j.cell.2024.08.043","article-title":"Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates","volume":"187","author":"Mucker","year":"2024","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","article-title":"An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge","volume":"15","author":"Freyn","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-031-57165-7_17","article-title":"Poxvirus Vaccines: Past, Present, and Future","volume":"1451","author":"Jhancy","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tang, D., Liu, X., Lu, J., Fan, H., Xu, X., Sun, K., Wang, R., Li, C., Dan, D., and Du, H. (2023). Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1203410"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41590-023-01715-7","article-title":"Rational design of a \u2018two-in-one\u2019 immunogen DAM drives potent immune response against mpox virus","volume":"25","author":"Wang","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","article-title":"A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease","volume":"187","author":"Zuiani","year":"2024","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2190647","DOI":"10.1080\/21505594.2023.2190647","article-title":"Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India","volume":"14","author":"Kumar","year":"2023","journal-title":"Virulence"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1016\/j.vaccine.2018.06.017","article-title":"Characterisation of putative immunomodulatory gene knockouts of lumpy skin disease virus in cattle towards an improved vaccine","volume":"36","author":"Kara","year":"2018","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chervyakova, O., Issabek, A., Sultankulova, K., Bopi, A., Kozhabergenov, N., Omarova, Z., Tulendibayev, A., Aubakir, N., and Orynbayev, M. (2022). Lumpy Skin Disease Virus with Four Knocked Out Genes Was Attenuated In Vivo and Protects Cattle from Infection. Vaccines, 10.","DOI":"10.3390\/vaccines10101705"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Douglass, N., Munyanduki, H., Omar, R., Gers, S., Mutowembwa, P., Heath, L., and Williamson, A.L. (2020). Influence of the Viral Superoxide Dismutase (SOD) Homologue on Lumpy Skin Disease Virus (LSDV) Growth, Histopathology and Pathogenicity. Vaccines, 8.","DOI":"10.3390\/vaccines8040664"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Mahony, T.J., Briody, T.E., and Ommeh, S.C. (2024). Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?. Vaccines, 12.","DOI":"10.3390\/vaccines12020152"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wolff, J., Beer, M., and Hoffmann, B. (2022). High Efficiency of Low Dose Preparations of an Inactivated Lumpy Skin Disease Virus Vaccine Candidate. Vaccines, 10.","DOI":"10.3390\/vaccines10071029"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/vr.135.18.434","article-title":"Protection of goats against capripox using a subunit vaccine","volume":"135","author":"Carn","year":"1994","journal-title":"Vet. Rec."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2009.05.031","article-title":"Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins","volume":"391","author":"Zheng","year":"2009","journal-title":"Virology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1080\/21645515.2017.1356497","article-title":"Plant-made vaccines and reagents for the One Health initiative","volume":"13","author":"Rybicki","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10529-021-03117-x","article-title":"Production of the sheep pox virus structural protein SPPV117 in tobacco chloroplasts","volume":"43","author":"Stanbekova","year":"2021","journal-title":"Biotechnol. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"905","DOI":"10.18699\/VJ20.689","article-title":"Transplastomic tobacco plants producing the hydrophilic domain of the sheep pox virus coat protein L1R","volume":"24","author":"Beisenov","year":"2020","journal-title":"Vavilov J. Genet. Breed."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100384","DOI":"10.1016\/j.jvacx.2023.100384","article-title":"Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development","volume":"15","author":"Ntombela","year":"2023","journal-title":"Vaccine X"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105943","DOI":"10.1016\/j.antiviral.2024.105943","article-title":"Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response","volume":"228","author":"Wen","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kakakhel, S., Ahmad, A., Mahdi, W.A., Alshehri, S., Aiman, S., Begum, S., Shams, S., Kamal, M., Imran, M., and Shakeel, F. (2023). Annotation of Potential Vaccine Targets and Designing of mRNA-Based Multi-Epitope Vaccine against Lumpy Skin Disease Virus via Reverse Vaccinology and Agent-Based Modeling. Bioengineering, 10.","DOI":"10.3390\/bioengineering10040430"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1111\/tbed.14718","article-title":"A candidate multi-epitope vaccine against Lumpy skin disease","volume":"69","author":"Uddin","year":"2022","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_99","first-page":"6401","article-title":"A one-health approach to design an mRNA-based vaccine candidate against the lumpy skin disease virus as an alternative to live-attenuated vaccines","volume":"27","author":"Naveed","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Okereke, M., Jayeola Oladipo, H., Deborah Aransiola, M., Oloruntoyin Adebowale, F., and Yusuf, H. (2022). The Urgent Need to Intensify Vaccine Development and Manufacturing in Africa: Lessons from Emerging Pandemics. Innov. Pharm., 13.","DOI":"10.24926\/iip.v13i4.5049"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41579-020-00441-3","article-title":"Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa","volume":"18","author":"Margolin","year":"2020","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:37:18Z","timestamp":1759919838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":101,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020186"],"URL":"https:\/\/doi.org\/10.3390\/v17020186","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}